Xencor swings to $39.4 million Q3 profit on $116.5 million revenue
Xencor reported third-quarter 2026 results, with revenue of $116.5 million, up from $21.0 million a year earlier, and net income attributable to Xencor of $39.4 million, or $0.50 per diluted share, compared with a net loss of $6.0 million a year earlier. Revenue came mainly from Alexion and Incyte royalties and a milestone from Astellas, while research and development spending rose, so shareholders should weigh the one-time items behind the profit against higher ongoing development costs.
Key points
- Q3 revenue was $116.5 million versus $21.0 million in Q3 2025, driven mainly by royalties from Alexion and Incyte and a milestone from Astellas.
- Q3 net income attributable to Xencor was $39.4 million, or $0.50 per diluted share, versus a net loss of $6.0 million, or $(0.08) per diluted share, a year earlier.
- R&D expenses rose to $84.3 million from $54.4 million, and G&A fell to $9.4 million from $14.2 million, which the company attributed to a non-recurring recovery of legal expenses.
- Cash, cash equivalents and marketable debt securities were $555.7 million at September 30, 2026, and Xencor expects to end 2026 with $480 million to $500 million.
The filing
Written by AI on Nov 7, 2026, 11:17 PM ET, from this filing only.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.